J. Boyd, Y. Sonoda, M. Federici, F. Bogomolniy, E. Rhei, D. Maresco, P. Saigo, L. Almadrones, R. Barakat, C. Brown, D. Chi, J. Curtin, E. Poynor, W. Hoskins (2000)
Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.JAMA, 283 17
W. Burke, M. Daly, J. Garber, J. Botkin, M. Kahn, P. Lynch, A. McTiernan, K. Offit, Jeffrey Perlman, G. Petersen, E. Thomson, C. Varricchio (1997)
Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.JAMA, 277 12
M. Schummer, W. Ng, Roger Bumgarner, P. Nelson, B. Schummer, D. Bednarski, L. Hassell, R. Baldwin, B. Karlan, L. Hood (1999)
Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas.Gene, 238 2
R. Hogg, M. Friedlander (2004)
Biology of epithelial ovarian cancer: implications for screening women at high genetic risk.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 7
Martin McIntosh, C. Drescher, B. Karlan, Nathalie Scholler, N. Urban, K. Hellstrom, Ingegerd Hellstrom (2004)
Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma.Gynecologic oncology, 95 1
D. Pauler, U. Menon, M. McIntosh, H. Symecko, S. Skates, I. Jacobs (2001)
Factors influencing serum CA125II levels in healthy postmenopausal women.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 10 5
R. Drapkin, H. Horsten, Yafang Lin, S. Mok, C. Crum, W. Welch, J. Hecht (2005)
Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas.Cancer research, 65 6
E. DeLong, D. DeLong, D. Clarke‐Pearson (1988)
Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.Biometrics, 44 3
R. Hassan, A. Remaley, M. Sampson, Jingli Zhang, D. Cox, J. Pingpank, R. Alexander, M. Willingham, I. Pastan, M. Onda (2006)
Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian CancerClinical Cancer Research, 12
D. Bamber (1975)
The area above the ordinal dominance graph and the area below the receiver operating characteristic graphJournal of Mathematical Psychology, 12
K. Lowe, C. Shah, E. Wallace, G. Anderson, P. Paley, M. McIntosh, M. Andersen, N. Scholler, Lindsay Bergan, Jason Thorpe, N. Urban, C. Drescher (2008)
Effects of Personal Characteristics on Serum CA125, Mesothelin, and HE4 Levels in Healthy Postmenopausal Women at High-Risk for Ovarian CancerCancer Epidemiology Biomarkers & Prevention, 17
W. Burke, G. Petersen, P. Lynch, J. Botkin, M. Daly, J. Garber, M. Kahn, A. McTiernan, K. Offit, E. Thomson, C. Varricchio (1997)
Recommendations for Follow-up Care of Individuals With an Inherited Predisposition to Cancer: I. Hereditary Nonpolyposis Colon CancerJAMA, 277
D. Levine, M. Federici, V. Reuter, J. Boyd (2002)
Cell proliferation and apoptosis in BRCA-associated hereditary ovarian cancer.Gynecologic oncology, 85 3
P. Shaw, J. McLaughlin, R. Zweemer, S. Narod, H. Risch, R. Verheijen, A. Ryan, F. Menko, P. Kenemans, Ian Jacobs (2002)
Histopathologic Features of Genetically Determined Ovarian CancerInternational Journal of Gynecological Pathology, 21
A. Antoniou, P. Pharoah, S. Narod, H. Risch, J. Eyfjord, J. Hopper, N. Loman, Hampus Olsson, O. Johannsson, Å. Borg, B. Pasini, P. Radice, S. Manoukian, D. Eccles, N. Tang, E. Oláh, H. Anton-Culver, E. Warner, J. Lubiński, J. Gronwald, B. Górski, H. Tulinius, S. Thorlacius, H. Eerola, H. Nevanlinna, K. Syrjäkoski, O. Kallioniemi, Deborah Thompson, Chris Evans, J. Peto, F. Lalloo, D. Evans, D. Easton (2003)
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.American journal of human genetics, 72 5
S. Skates, N. Horick, D. Finkelstein, K. Lu (2002)
Prospective multicenter ovarian cancer screening trial of women at high risk: Preliminary results from the first 2,200 women.
Stata Statistical Software. College Station, TX: StataCorp LP
S. Lakhani, S. Manek, F. Penault-Llorca, A. Flanagan, Laurent Arnout, Samantha Merrett, L. McGuffog, D. Steele, P. Devilee, J. Klijn, H. Meijers-Heijboer, P. Radice, S. Pilotti, H. Nevanlinna, R. Butzow, H. Sobol, J. Jacquemier, D. Lyonet, S. Neuhausen, B. Weber, T. Wagner, R. Winqvist, Y. Bignon, F. Monti, F. Schmitt, G. Lenoir, S. Seitz, Ute Hamman, P. Pharoah, G. Lane, B. Ponder, D. Bishop, D. Easton (2004)
Pathology of Ovarian Cancers in BRCA1 and BRCA2 CarriersClinical Cancer Research, 10
J. Creaney, I. Bruggen, M. Hof, A. Segal, A. Musk, N. Klerk, N. Horick, S. Skates, B. Robinson (2007)
Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.Chest, 132 4
I. Hellström, J. Raycraft, M. Hayden-Ledbetter, J. Ledbetter, M. Schummer, M. McIntosh, C. Drescher, N. Urban, K. Hellström (2003)
The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.Cancer research, 63 13
U. Menon, M. Burnell, Aarti Sharma, A. Gentry-Maharaj, L. Fraser, A. Ryan, M. Parmar, M. Hunter, I. Jacobs (2007)
Decline in use of hormone therapy among postmenopausal women in the United KingdomMenopause, 14
Lindsay Bergan, Jennifer Gross, B. Nevin, N. Urban, N. Scholler (2007)
Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/Mesothelin-dependent cell attachment.Cancer letters, 255 2
T. Pal, Jennifer Permuth‐Wey, J. Betts, J. Krischer, J. Fiorica, H. Arango, J. Lapolla, M. Hoffman, M. Martino, K. Wakeley, G. Wilbanks, S. Nicosia, A. Cantor, R. Sutphen (2005)
BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma casesCancer, 104
(2009)
Cancer Epidemiology, Biomarkers & Prevention Cancer Epidemiol Biomarkers Prev
W. Burke, M. Daly, J. Garber, J. Botkin, M. Kahn, P. Lynch, A. McTiernan, K. Offit, J. Perlman, G. Petersen, E. Thomson, C. Varricchio (1997)
Recommendations for follow-up care of individuals with an inherited predisposition to Cancer. II. BRCA1 and BRCA2JAMA, 277
H. Risch, J. McLaughlin, D. Cole, B. Rosen, L. Bradley, E. Kwan, E. Jack, D. Vesprini, G. Kuperstein, J. Abrahamson, I. Fan, B. Wong, S. Narod (2001)
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.American journal of human genetics, 68 3
R. Bast, D. Badgwell, Zhimin Lu, Rebecca Marquez, D. Rosen, Jiaxin Liu, K. Baggerly, E. Atkinson, S. Skates, Zhen Zhang, A. Lokshin, U. Menon, I. Jacobs, K. Lu (2005)
New tumor markers: CA125 and beyondInternational Journal of Gynecologic Cancer, 15
N. Scholler, K. Lowe, Lindsay Bergan, Archana Kampani, V. Ng, Robin Forrest, Jason Thorpe, Jennifer Gross, B. Garvik, R. Drapkin, G. Anderson, N. Urban (2008)
Use of Yeast-Secreted In vivo Biotinylated Recombinant Antibodies (Biobodies) in Bead-Based ELISAClinical Cancer Research, 14
M. Yen, Chih‐Yi Hsu, T. Mao, T. Wu, R. Roden, Tian-Li Wang, I. Shih (2006)
Diffuse Mesothelin Expression Correlates with Prolonged Patient Survival in Ovarian Serous CarcinomaClinical Cancer Research, 12
D. Rosen, Lin Wang, J. Atkinson, Yin-hua Yu, K. Lu, E. Diamandis, I. Hellstrom, S. Mok, Jinsong Liu, R. Bast (2005)
Potential markers that complement expression of CA125 in epithelial ovarian cancer.Gynecologic oncology, 99 2
Chia‐Yen Huang, W. Cheng, Chien-Nan Lee, Yidi Su, S. Chien, Yu-Lin Tzeng, C. Hsieh, Chi-An Chen (2006)
Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor.Anticancer research, 26 6C
D. Purnomosari, G. Pals, A. Wahyono, T. Aryandono, T. Manuaba, S. Haryono, P. Diest (2007)
BRCA1 and BRCA2 germline mutation analysis in the Indonesian populationBreast Cancer Research and Treatment, 106
M. Pepe, G. Longton (2005)
Standardizing Diagnostic Markers to Evaluate and Compare Their PerformanceEpidemiology, 16
A. Jazaeri, C. Yee, C. Sotiriou, Kelly Brantley, J. Boyd, E. Liu (2002)
Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.Journal of the National Cancer Institute, 94 13
N. Scholler, M. Crawford, Alicia Sato, C. Drescher, K. O'Briant, N. Kiviat, G. Anderson, N. Urban (2006)
Bead-Based ELISA for Validation of Ovarian Cancer Early Detection MarkersClinical Cancer Research, 12
Cancer Epidemiology Biomarkers & Prevention – Unpaywall
Published: May 1, 2009
Access the full text.
Sign up today, get DeepDyve free for 14 days.